Skip to content
FrontierPicks

Watching

PM · Philip Morris International

Conviction · Low · more likely to lag the S&P 500 over the next three months

Wrong if: a daily close above $214.35

Business pivot Catalyst ·

Note written ·

Price against the kill line

9.3% clear of its kill line on the 17 November 2026 close.

How to read this

This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 17 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.

The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.

The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides

PMPhilip Morris International
$214.35
$194.38
9.3%well clear

Three months against the kill line

PM daily closes from 19 August 2026 to 17 November 2026, last $194.38, against its kill line: a daily close above $214.35. 19 August 2026: $188.3220 August 2026: $189.8921 August 2026: $186.6324 August 2026: $189.8325 August 2026: $192.2726 August 2026: $192.4527 August 2026: $188.8628 August 2026: $190.2631 August 2026: $185.711 September 2026: $185.562 September 2026: $186.343 September 2026: $184.594 September 2026: $180.988 September 2026: $183.169 September 2026: $184.1310 September 2026: $188.1611 September 2026: $189.4414 September 2026: $193.2015 September 2026: $192.4616 September 2026: $190.0817 September 2026: $188.8618 September 2026: $187.0221 September 2026: $185.8922 September 2026: $188.6123 September 2026: $189.2224 September 2026: $189.8725 September 2026: $188.8628 September 2026: $192.1129 September 2026: $192.2530 September 2026: $189.201 October 2026: $186.582 October 2026: $187.465 October 2026: $189.536 October 2026: $190.407 October 2026: $192.698 October 2026: $200.509 October 2026: $201.1912 October 2026: $202.0013 October 2026: $199.2914 October 2026: $205.5815 October 2026: $199.9016 October 2026: $205.2019 October 2026: $201.0520 October 2026: $199.9021 October 2026: $197.4622 October 2026: $201.7423 October 2026: $199.4726 October 2026: $201.8727 October 2026: $202.6228 October 2026: $202.6429 October 2026: $208.5030 October 2026: $208.792 November 2026: $208.293 November 2026: $208.034 November 2026: $211.285 November 2026: $201.506 November 2026: $197.889 November 2026: $193.1210 November 2026: $194.2511 November 2026: $196.3512 November 2026: $196.6613 November 2026: $198.9616 November 2026: $196.0417 November 2026: $194.38

Daily closes, to . Red: the kill line, a daily close above $214.35, set on 15 November 2026. The shares are up 3.2% since the close; the S&P 500 is down 4.5% over the same sessions. Figures in the note can cover a different window.

Kill line

A daily close above $214.35, above the 30 October 2026 52-week high, which would show the shares leading; or fourth-quarter 2026 U.S. operating income clearly above the "around zero" management guided on 21 October 2026.

Research onlyNot in the portfolio.

Catalyst

The portfolio's record →

The business · as of

Philip Morris International sells Marlboro cigarettes and smoke-free nicotine products, mainly IQOS heated tobacco and ZYN nicotine pouches, to wholesalers and retailers worldwide. It earns money mostly through price increases on steady volumes. Revenue was $11,438 million in the quarter to 30 September 2026.

What is changing, and what follows · as of

What is changing now
On 21 October 2026 the company reported third-quarter revenue up 5.5% to $11,438 million. It is moving most U.S. ZYN cans from 15 to 20 pouches at the same price, about 25% less revenue per pouch.
What follows for the company
Management expects U.S. operating income to fall from $171 million in the third quarter to around zero in the fourth as U.S. spending rises. It guides organic operating income growth to the middle or lower half of 7–9%.
What follows for its customers, suppliers and competitors
More ZYN pouches for the same price adds pressure on Altria (MO), whose on! brand held 13.4% of U.S. pouch sales in the first quarter according to TIKR, and on British American Tobacco (BTI).

What the price assumes · as of

At the 13 November 2026 close (filed inputs to 23 October 2026) the shares trade at 29.0 times earnings, 21.1 times EV/EBIT and 8.1 times sales, with a 4.4% free-cash-flow yield. That holds only if revenue keeps growing near the 5.5% of the latest filed quarter and the operating margin stays near that quarter's 42.5% through the U.S. ZYN price reset.

Key figures from the filings · Consumer Staples

Quarter to 30 September 2026, filed 23 October 2026; valuation at the 17 November 2026 close

Revenue, latest quarter ($M)
11,438
Revenue, change on a year (%)
+5.5
Gross margin (%)
68.7
Operating margin (%)
42.5
Free cash flow, four quarters ($M)
13,595
Net cash, cash less debt ($M)
−40,879
Price to earnings (×)
28.3
Enterprise value to sales (×)
8.0
All filed numbers

What Philip Morris International reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Results by quarter Each quarter with the day its figures were first filed, and the day of a later filing that changed them
Quarter to Revenue ($M) On a year (%) Gross margin (%) Operating margin (%)
first filed 11,438 +5.5 68.7 42.5
first filed 11,192 +10.4 68.4 40.5
first filed 10,146 +9.1 68.1 38.4
first filed 10,362 +6.8 65.6 32.6
first filed restated 10,845 +9.4 67.9 39.3
first filed restated 10,140 +7.1 67.7 36.6
Income Quarter to 30 September 2026, filed 23 October 2026
Pre-tax income ($M) 4,594
Net income ($M) four quarters: 10,709 3,313
Diluted shares, change on a year (%) against the quarter to 30 September 2025 +0.1
Cash flow Four quarters to 30 September 2026, filed 23 October 2026
Operating cash flow ($M) 15,154
Capital spending ($M) 1,559
Free cash flow ($M) 13,595
Balance sheet At 30 September 2026, filed 23 October 2026
Cash and short-term investments ($M) 6,683
Debt ($M) long-term debt and finance leases plus short-term borrowings 47,562
Net cash, cash less debt ($M) −40,879
Deferred revenue ($M) Not reported
Backlog, orders not yet delivered ($M) Not reported
Receivables ($M) 5,156
Inventory ($M) 10,326
Shareholders' equity ($M) −7,937
Valuation At the 17 November 2026 close, filed figures to 23 October 2026
Market value ($M) 302,972
Enterprise value, market value plus net debt ($M) 343,851
Enterprise value to sales (×) 8.0
Enterprise value to operating income (×) 20.6
Price to earnings (×) 28.3
Price to book value (×) Not meaningful
Free-cash-flow yield (%) 4.5

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 0.9% of shares outstanding sold short, 3.2 days of average trading to cover, −14.0% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Competitors:
MO, BTI

The thesis

Philip Morris International is more likely to lag the S&P 500 over the next three months. The shares trade at 29.0 times earnings while management has guided U.S. ZYN profit to around zero in the fourth quarter of 2026. The fourth-quarter report and the 2027 outlook, expected in early February 2027, settle it.

The rating is Low because the business is growing but the next report carries a guided profit dip. On 21 October 2026 the company reported third-quarter revenue of $11,438 million, up 5.5% from a year earlier and 7.1% organically, and adjusted diluted earnings per share (EPS) of $2.36, up 5.4%. In the same release it kept its ex-currency 2026 adjusted EPS forecast at $8.11–8.26 and cut the expected currency benefit to $0.18 from $0.24. It also guided organic operating income growth to the middle or lower half of its 7–9% range.

The main problem is the U.S. pouch business. Most flagship ZYN cans are moving from 15 to 20 pouches at the same price. On the 22 October 2026 call, finance chief Massimo Andolina said this means about 25% less revenue per pouch, according to TIKR. Management expects U.S. operating income, $171 million in the third quarter, to be "around zero or slightly negative" in the fourth.

Bullish and bearish views on Philip Morris International Inc.

The bull case on Philip Morris International Inc. (PM), in brief: pricing still drives record profits. The bear case: U.S. profit has fallen sharply.

Bull case

  • Pricing still drives record profits. The 21 October 2026 release showed $739 million of favourable pricing in the third quarter and record quarterly revenue, gross profit and operating income. The operating margin was 42.5% in the quarter to 30 September 2026, against 39.3% a year earlier (10-Q filed 23 October 2026).
  • Cigarette volumes are holding up better than planned. Cigarette volume was flat in the third quarter and down 1.2% over the first nine months of 2026. On 21 October 2026 the company dropped its earlier assumption of a 2–3% full-year decline.
  • Cash funds a rising dividend. Free cash flow was $13,595 million over the four quarters to 30 September 2026 (10-Q). On 21 October 2026 the board raised the quarterly dividend 8.8% to $1.60.
  • Smoke-free sales are now a large share of revenue. Smoke-free products made up more than 40% of third-quarter net revenue and about 42% of the year to date (21 October 2026 release). IQOS heated-tobacco shipments rose 1.5% to 41.5 billion units.
  • Some analysts see room above the price. Stifel kept a Buy rating and raised its target to $232 from $205 on 3 November 2026. Argus raised its target to $220 on 26 October 2026.

Bear case

  • U.S. profit has fallen sharply. U.S. adjusted operating income fell 41.1% organically to $550 million over the first nine months of 2026 (21 October 2026 release). Management expects U.S. selling and administrative costs, about $370 million in the third quarter, to rise another 10% in the fourth, according to TIKR's 22 October 2026 summary of the call.
  • ZYN growth has slowed. U.S. ZYN shipments rose only 4.2% to 3.2 billion pouches in the third quarter (21 October 2026 release). A Jefferies analyst cited scanner data showing a mid-single-digit fall in U.S. ZYN volumes over the same quarter, as reported by TIKR on 22 October 2026.
  • The valuation already assumes growth. At the 13 November 2026 close the shares trade at 29.0 times reported earnings and 21.1 times operating profit including debt. TIKR put the forward multiple at 21.97 times on 22 October 2026, against a five-year average of 17.85 times.
  • Balance sheet leaves no room for buybacks. Debt was $47,562 million and shareholders' equity was negative $7,937 million at 30 September 2026 (10-Q). The company said on 21 October 2026 that it plans no share repurchases in 2026.
  • The newest analyst rating sits at the price. JPMorgan reinstated coverage at Neutral with a $200 target on 10 November 2026.
  • Regulation keeps tightening. On 29 October 2026 the UK health department extended its under-18 sales ban to nicotine products and all vapes. On 12 November 2026 Politico reported that European cities are asking for an EU-wide ban on cigarette filters.

Price setup

The shares closed at $198.96 on 13 November 2026. That is 7.2% below the 52-week intraday high of $214.35 set on 30 October 2026, and 8.8% above the adjusted close three months earlier. The 50-day moving average is $195.68 and the 200-day moving average is $180.97, both from adjusted daily closes as of 13 November 2026. The 52-week closing low was $147.81 on 5 December 2025.

On report day, 21 October 2026, the shares closed at $197.46, down 1.22%, after trading near $194 (TIKR). They then rose to the 30 October 2026 high and fell back to close at $193.12 on 9 November 2026, below the 50-day average. They recovered to $198.96 by 13 November 2026. The price now sits just above the 50-day average and near JPMorgan's $200 target. A move back above the October high would mean investors are looking past the fourth-quarter profit dip.

Catalysts ahead

  • ~29 January 2027 (est.): Altria fourth-quarter 2026 report. Altria's on! pouch results show whether the cheaper ZYN cans are winning share from the main U.S. competitor.
  • ~5 February 2027 (est.): Philip Morris International fourth-quarter 2026 results and 2027 outlook. This report shows whether U.S. operating income fell to around zero as guided, and whether 2027 EPS guidance supports a multiple of 29.0 times earnings.
  • ~16 February 2027 (est.): CAGNY consumer conference presentation. Management usually restates or updates the year's forecast at this conference, which shows whether the 2027 outlook holds.

What would change the view

A daily close above $214.35, above the 30 October 2026 52-week high, which would show the shares leading; or fourth-quarter 2026 U.S. operating income clearly above the "around zero" management guided on 21 October 2026.

What it trades with

A common market view is that tobacco shares trade as defensive holdings that lag when growth stocks rally. On 9 November 2026 the Nasdaq 100 rose 3% as chip stocks rebounded, and Philip Morris fell from $197.88 to $193.12. The shares are most closely linked to news from Altria (MO), which competes with ZYN through on!, and from British American Tobacco (BTI). Most revenue is earned outside the United States, so the dollar affects reported EPS. The 21 October 2026 cut to the currency benefit, to $0.18 from $0.24, shows how currency moves feed into the forecast.

Caveats

  • Shareholders' equity is negative, at −$7,937 million at 30 September 2026, against debt of $47,562 million, so price-to-book is not a meaningful measure for this company. Form 10-Q for the third quarter of 2026 · as of
The evidence, claim by claim (8)
  1. Third-quarter 2026 net revenue was $11.4 billion, up 5.5% reported and 7.1% organically; adjusted diluted EPS was $2.36, up 5.4%, and reported diluted EPS was $2.12, down 4.9%. PMI third-quarter 2026 results release · as of
  2. The 2026 adjusted diluted EPS forecast is $8.29–8.44; the ex-currency range of $8.11–8.26 is unchanged, and the currency benefit was cut to $0.18 from $0.24. PMI third-quarter 2026 results release · as of
  3. U.S. ZYN shipments rose 4.2% to 3.2 billion pouches in the third quarter, and IQOS heated-tobacco unit shipments rose 1.5% to 41.5 billion. PMI third-quarter 2026 results release · as of
  4. U.S. adjusted operating income was $171 million in the third quarter, and fell 41.1% organically to $550 million over the first nine months of 2026. PMI third-quarter 2026 results release · as of
  5. Management guided U.S. operating income to around zero or slightly negative in the fourth quarter of 2026, as ZYN moves to 20-pouch cans at about 25% less revenue per pouch. 21 October 2026 earnings call, as reported by TIKR · as of
  6. The quarterly dividend was raised 8.8% to $1.60, and the company plans no share repurchases in 2026. PMI third-quarter 2026 results release · as of
  7. Operating margin was 42.5% in the quarter to 30 September 2026, against 39.3% a year earlier; free cash flow was $13,595 million over the four quarters to that date. Form 10-Q for the third quarter of 2026 · as of
  8. JPMorgan reinstated coverage at Neutral with a $200 price target on 10 November 2026, after Stifel kept a Buy rating and raised its target to $232 from $205 on 3 November 2026. Benzinga analyst ratings reports · as of

Sources

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X